Skip to main navigation Skip to search Skip to main content

Neonatal mortality and morbidity in Down syndrome in the time of prenatal aneuploidy testing: a retrospective cohort study

  • Amsterdam UMC location University of Amsterdam
  • Amsterdam Public Health
  • Amsterdam UMC
  • St. Antonius Ziekenhuis
  • Department of Orthopaedic Surgery, Flevoziekenhuis, Almere, The Netherlands
  • Spaarne Gasthuis, Hoofddorp, The Netherlands
  • KU Leuven
  • Departments of Anesthesiology, Alrijne Hospital, Leiderdorp, The Netherlands
  • Vrije Universiteit Amsterdam
  • Department of Pediatrics, National Defense Medical College, Saitama, Japan; Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan.

Research output: Contribution to journalArticleAcademicpeer-review

25 Downloads (Pure)

Abstract

The total uptake of prenatal aneuploidy screening for Down syndrome (DS) is increasing worldwide. As a result of increasing prenatal diagnosis of DS and subsequent termination of pregnancy, livebirth prevalence of DS is decreasing. The aim of this study is to explore the impact of an increasing uptake of prenatal aneuploidy screening on the neonatal mortality and morbidity in DS. This is a retrospective cohort study of 253 neonates with DS born between 2012 and 2018 that were seen at the outpatient clinic of five hospitals in the Netherlands. The medical files were reviewed for maternal and neonatal characteristics and neonatal morbidities. The Dutch national birth registry (Perined) provided mortality numbers of neonates with DS. The results were interpreted in the context of other published studies. Neonatal mortality in DS remained stable, ranging from 1.4 to 3.6%. A congenital heart defect (CHD) was found in 138 of the 251 neonates (55.0%) with atrial septal defect, atrioventricular septal defect, and ventricular septal defect being the most common. The type of CHD in DS did not change over time. Gastro-intestinal defects were present in 22 of the 252 neonates with DS (8.7%), with duodenal atresia as the most reported anomaly. Persistent pulmonary hypertension of the neonate (PPHN) was found in 31 of the 251 infants (12.4%). Conclusions: Although uptake of prenatal aneuploidy screening increased, neonatal mortality and morbidity in DS appears to be stable. An increased incidence of PPHN was found.What is Known:• The total uptake of prenatal aneuploidy screening for Down syndrome is increasing worldwide.• As a result of increasing prenatal diagnosis of Down syndrome and subsequent termination of pregnancy, the livebirth prevalence of Down syndrome is decreasing.What is New:• Although uptake of prenatal aneuploidy screening increased, neonatal mortality and morbidity in Down syndrome appears to be stable.• An increased incidence of persistent pulmonary hypertension of the neonate was found.
Original languageEnglish
Pages (from-to)319-328
Number of pages10
JournalEuropean journal of pediatrics
Volume182
Issue number1
Early online date9 Nov 2022
DOIs
Publication statusPublished - Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Congenital defects
  • Down syndrome
  • Neonatal morbidity
  • Neonatal mortality
  • Persistent pulmonary hypertension of the neonate
  • Prenatal aneuploidy screening

Fingerprint

Dive into the research topics of 'Neonatal mortality and morbidity in Down syndrome in the time of prenatal aneuploidy testing: a retrospective cohort study'. Together they form a unique fingerprint.

Cite this